What Are The Chances Of Zymeworks BC Inc (NASDAQ: ZYME) Becoming A Clear Buy?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. The stock was recently discussed on Yahoo Finance as it revealed that Zymeworks Announces Participation in Upcoming Investor Conferences.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

As a NASDAQ listed company, ZYME falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Zymeworks BC Inc is $808.24M. A total of 0.28 million shares were traded on the day, compared to an average of 470.64K shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, ZYME has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 4 BUYs and 1 SELLs from insiders. Insiders purchased 3,555,208 shares during that period but sold 2,977.

In the most recent transaction, Galbraith Kenneth sold 5,706 shares of ZYME for 11.22 per share on Jan 08. After the transaction, the Chair & CEO now owns 23,762 company shares. In a previous transaction on Jan 08, Moore Paul Andrew sold 2,339 shares at 11.22 per share. ZYME shares that Chief Scientific Officer owns now total 7,367.

Among the insiders who sold shares, Astle Christopher disposed of 1,431 shares on Jan 08 at a per-share price of $11.22. This resulted in the SVP & Chief Financial Officer holding 6,503 shares of ZYME after the transaction. In another insider transaction, Galbraith Kenneth sold 18,198 shares at $10.65 per share on Jan 05. Company shares held by the Chair & CEO now total 29,468.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ZYME has a high of $11.68 and a low of $6.01.

As of this writing, ZYME has an earnings estimate of -$0.43 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.23 per share and a lower estimate of -$0.69. The company reported an EPS of -$0.76 in the last quarter, which was -61.70% lower than expectations of -$0.47.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ZYME’s latest balance sheet shows that the firm has $252.61M in Cash & Short Term Investments as of fiscal 2021. There were $32.33M in debt and $71.85M in liabilities at the time. Its Book Value Per Share was $6.19, while its Total Shareholder’s Equity was $249.09M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Buy with a score of 4.33.

Most Popular

Related Posts